Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Holding LRMR?
Track your performance easily
LRMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $13.68
Previous Close$6.13
Volume402.09K
Average Volume (3M)710.55K
Market Cap
$391.13M
Enterprise Value$192.79M
Total Cash (Recent Filing)$203.71M
Total Debt (Recent Filing)$5.36M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 12, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding63,806,628
10 Day Avg. Volume897,700
30 Day Avg. Volume710,552
Standard Deviation0.26
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.96
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$20.43Price Target Upside231.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Larimar Therapeutics News
PremiumCompany Announcements
Larimar Therapeutics Q3 2024 Financial Update
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company holds a strong balance sheet with $226 million in cash, providing financial runway into 2026.
Innovative Treatment PotentialNomlabofusp shows potential as a recombinant fusion protein engineered to restore frataxin protein expression, offering a logical treatment strategy for Friedreich's ataxia.
Regulatory AdvancementsNomlabofusp previously received Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation from the FDA.
Bears Say
Clinical TrialsLow bandwidth at academic study centers has driven slower than anticipated site activation and ultimately, slower progression to the 50mg dose.
Regulatory ApprovalIf the FDA does not accept frataxin levels as an endpoint or if it does not accept the submission of nomlabofusp for accelerated approval, then the stock price would decline.
Research And Development RiskThere is an additional layer of risk since frataxin is not currently an accepted surrogate endpoint, and thus Larimar Therapeutics needs to produce evidence that frataxin levels can predict clinical benefit.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $3.19 and its highest was $13.68 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 12, 2025 which is in 109 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Oct 30, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.375 by $0.135.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -$0.31.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 63,806,630 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.375. Following the earnings report the stock price went up 8.74%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Among the largest hedge funds holding Larimar Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Larimar Therapeutics, Inc.’s shares valued at 139M.
---
Larimar Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.43 (231.66% Upside)
$20.43 (231.66% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 14.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
99.02%
12-Months-Change
Fundamentals
Return on Equity
-44.50%
Trailing 12-Months
Asset Growth
110.69%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
---
LRMR Stock 12 Month Forecast
Average Price Target
$20.43
▲(231.66% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
TRACON Pharmaceuticals
―
Galera Therapeutics
―
Aclaris Therapeutics
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+58.16%
reiterated a buy rating 10 months ago
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +58.16% per trade.
---